EFFICIENT CELL-FREE SELECTION OF ANTIBODIES

高效的无细胞抗体选择

• 批准号: 6294474
• 负责人: Jiwu Wang
• 金额: $ 9.97万
• 依托单位: ALLELE BIOTECHNOLOGY AND PHARMACEUTICALS
• 依托单位国家: 美国
• 财政年份: 2001
• 资助国家: 美国
• 起止时间: 2001-03-15 至 2002-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6294474
• 关键词: binding proteins; biomedical equipment development; cell free system; complementary DNA; genetic library; high throughput technology; immunologic substance development /preparation; monoclonal antibody

DESCRIPTION: The objective of this proposal is to develop a novel cell-free system that would facilitate rapid selection of functional fragments of monoclonal antibodies. The system descibed is based on well-established molecular mechanisms. For antibody selection, a cDNA library encoding the single-chain variable region fragment (scFv) can be used in an in vitro system to generate a large pool of scFv's that can be selected with target antigens. The cDNA for the desired scFv can be recovered and used to express large quantities of recombinant scFv. This procedure is more efficient, less expensive and technically easier than all existing methods for antibody selection. It also has the potential to be adapted to high throughput screening systems, or modified to screen binding proteins other than antibodies. PROPOSED COMMERCIAL APPLICATION: The goal for the phase I studies is to test the feasibility of this innovative technology. Once developed, it may have a major impact on proteomics, cancer diagnosis and drug development.

描述：该提议的目的是开发一个新颖的细胞 可以促进快速选择功能片段的系统 单克隆抗体。该系统基于建立的 分子机制。对于抗体选择，编码cDNA库 单链可变区域碎片（SCFV）可用于体外 生成可以选择目标选择的大量SCFV的系统 抗原。可以回收所需的SCFV的cDNA，并用于表达 大量重组SCFV。此过程更有效，更少 比所有现有的抗体选择方法都昂贵且技术更容易。 它还有可能适应高吞吐量筛选系统或 修改为筛选结合蛋白以外的其他抗体。 拟议的商业应用： I阶段研究的目标是测试这种创新技术的可行性。 一旦开发，它可能会对蛋白质组学，癌症诊断和药物产生重大影响 发展。